FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma

The FDA approved Opdivo in combination with cisplatin and gemcitabine for first-line treatment of adult patients ...

MARCH 7, 2024

Balversa Approved for Locally Advanced or Metastatic Urothelial Carcinoma

The FDA approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic ...

JANUARY 22, 2024

Padcev With Keytruda Approved for Locally Advanced or Metastatic Urothelial Carcinoma

The FDA gave accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab ...

APRIL 5, 2023

Maintenance Rucaparib After Chemo Extends PFS in Some Metastatic Urothelial Cancers

Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib following platinum-based ...

APRIL 18, 2022

Padcev Granted Regular Approval for Locally Advanced or Metastatic UC

The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat some adults with locally advanced or ...

JULY 19, 2021

FDA Approves First FGFR Kinase Inhibitor for Advanced Bladder Ca

The FDA granted accelerated approval to erdafitinib (Balversa, Janssen) for the treatment of adults with locally ...

APRIL 17, 2019

FDA Approves Tecentriq for Urothelial Carcinoma

Tecentriq is the only anti–PD-L1 cancer immunotherapy approved by the FDA.

MAY 19, 2016